Patent for the production of Immunicum's therapeutic cancer vaccines to be granted in Europe

Gothenburg, Sweden, 2015-01-27 15:10 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the European Patent Office (EPO) has announced its intention to grant a patent pertaining to the production method of the Company's therapeutic cancer vaccines.

 

- We are pleased with the positive news from the European Patent Office, which will further strengthen the intellectual property protection for our therapeutic cancer vaccines, says Jamal El-Mosleh, CEO of Immunicum.

The announcement from the EPO relates to a patent titled "Co-Differentiation Of Monocytes From Allogeneic Donors", covering a significant part of the production method of Immunicum's therapeutic cancer vaccines.

Immunicum's vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a unique refinement process are developed into highly immunogenic cells. The Company's unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells.

 

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

 

The company's Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31. www.redeye.se

 

About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the company's most advanced project - INTUVAX® against renal cancer - is expected to start in early 2015. The project portfolio contains three further projects, including a clinical phase I/II-study in liver cancer.

www.immunicum.com